健康社区老年人潜在不适当用药与残疾风险增加相关
基于ASPREE临床试验19,114名70岁以上(美国少数族裔65岁以上)无重大心血管疾病、认知障碍或显著躯体残疾的社区老年人,按改良2019 AGS Beers标准定义PIMs。基线39%使用至少一种PIM,PIM暴露与持续性躯体残疾(aHR 1.47)和住院(aHR 1.26)风险增加相关,但无残疾生存率和死亡率无显著差异。
要点
- 基线39%的社区老年人使用至少一种PIM。
- PIM暴露与持续性躯体残疾风险增加相关(aHR 1.47)。
- PIM暴露与住院风险增加相关(aHR 1.26)。
核心结论
- PIM暴露与随后新发残疾和住院风险增加相关。
- 住院前残疾风险增加提示PIM使用可能启动健康老年人的残疾级联。
- 研究结果强调对 otherwise good health 的老年人处方PIM时需谨慎。
研究设计与样本
- ASPREE临床试验队列分析,纳入19,114名70岁以上(美国少数族裔65岁以上)社区居住老年人。
- 纳入者无重大心血管疾病、认知障碍或显著躯体残疾。
- PIM按改良2019 AGS Beers标准定义,采用Cox比例风险回归模型分析基线PIM暴露与结局的关联。
主要发现
- 基线时7396人(占总人数39%)被处方至少一种PIM。
- PIM暴露组与未暴露组相比,持续性躯体残疾风险增加(aHR 1.47,95%CI 1.21-1.80)。
- PIM暴露组与未暴露组相比,住院风险增加(aHR 1.26,95%CI 1.20-1.32)。
- PIM暴露组与未暴露组相比,无残疾生存率(aHR 1.02,95%CI 0.93-1.13)和死亡风险(aHR 0.92,95%CI 0.81-1.05)无显著差异。
- 交互分析中,这些效应不因多重用药状态而异;PPIs、抗精神病药和苯二氮䓬类药物与残疾风险增加相关。
关键数值与推荐
- PIM定义依据改良2019 AGS Beers标准。
- 基线PIM暴露与持续性躯体残疾的调整HR为1.47(95%CI 1.21-1.80)。
- 基线PIM暴露与住院的调整HR为1.26(95%CI 1.20-1.32)。
- PIM暴露与残疾后住院的调整HR为1.92(95%CI 1.25-2.96),住院后残疾的调整HR为1.54(95%CI 1.15-2.05)。
临床怎么用
- 在健康社区老年人中处方PIM时需谨慎。
- 关注PPIs、抗精神病药和苯二氮䓬类等与残疾风险增加相关的药物。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efforts to minimize medication risks among older adults include avoidance of potentially inappropriate medications (PIMs). However, most PIMs research has focused on older people in aged or inpatient care, creating an evidence gap for community-dwelling older adults. To address this gap, we investigated the impact of PIMs use in the ASPirin in Reducing Events in the Elderly (ASPREE) clinical trial cohort. METHODS: Analysis included 19,114 community-dwelling ASPREE participants aged 70+ years (65+ if US minorities) without major cardiovascular disease, cognitive impairment, or significant physical disability. PIMs were defined according to a modified 2019 AGS Beers Criteria. Cox proportional-hazards regression models were used to estimate the association between baseline PIMs exposure and disability-free survival, death, incident dementia, disability, and hospitalization, with adjustment for sex, age, country, years of education, frailty, average gait speed, and comorbidities. RESULTS: At baseline, 7396 (39% of the total) participants were prescribed at least one PIM. Compared with those unexposed, participants on a PIM at baseline were at an increased risk of persistent physical disability (adjusted hazard ratio [HR] 1.47, 95% confidence interval [CI] 1.21, 1.80) and hospitalization (adjusted HR 1.26, 95% CI 1.20, 1.32), but had similar rates of disability-free survival (adjusted HR 1.02; 95% CI 0.93, 1.13) and death (adjusted HR 0.92, 95% CI 0.81, 1.05). These effects did not vary by polypharmacy status in interaction analyses. PIMs exposure was associated with higher risk of disability followed by hospitalization (adjusted HR 1.92, 95% CI 1.25, 2.96) as well as vice versa (adjusted HR 1.54, 95% CI 1.15, 2.05). PPIs, anti-psychotics and benzodiazepines, were associated with increased risk of disability. CONCLUSIONS: PIMs exposure is associated with subsequent increased risk of both incident disability and hospitalization. Increased risk of disability prior to hospitalization suggests that PIMs use may start the disability cascade in healthy older adults. Our findings emphasize the importance of caution when prescribing PIMs to older adults in otherwise good health.
引用
- Lockery JE, Collyer TA, Woods RL, et al. Potentially inappropriate medication use is associated with increased risk of incident disability in healthy older adults. J Am Geriatr Soc. 2023. PMID: 37039393. doi:10.1111/jgs.18353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。